Clinical Trials
Blood Cells Generated In Lab Transfused Into First Patients
In the first clinical trial of its sort, lab-grown blood cells were administered to a second patient, potentially paving the way for future therapies for blood disorders like sickle cell.
At the NHS Blood and Transplant (NHSBT) Advanced Therapies Unit...
Clinical Trials
First Simulated Drug Study Examines 2 Alzheimer Treatments
The effectiveness of aducanumab and donanemab in treating Alzheimer's disease (AD) was successfully simulated using a novel computer model, demonstrating how a steady rise in dosage until reaching the maximum dose helps to minimize cognitive loss and limit adverse...
Clinical Trials
Cancer Clinical Trials Begin On New Platform In Melbourne
By comparing tumour samples taken before and after treatment, a new clinical trial platform called Brain-POP (brain perioperative) will allow doctors to precisely see how a new medication therapy affects a patient's brain cancer.
The project, which the Brain Cancer...
Clinical Trials
Epilepsy Patients To Receive Brain Laser Therapy From NHS
The NHS has made public its intentions to provide an avant-garde laser therapy for patients with epilepsy who have not previously responded well to existing treatments, known as laser interstitial thermal therapy (LITT).
Up to 150 NHS patients might possibly...
Clinical Trials
Over Five Years, Clinical Studies In The UK Have Plunged
An industry analysis on October 20th revealed that the number of clinical trials launched annually in Britain decreased by 41% between 2017 and 2021, creating a "clear and significant threat" to its reputation as a destination for clinical research.
The...
Clinical Trials
Pistoia Alliance To Explore Clinical Trial Ecology Influence
The Clinical Trials Environmental Impact Community of Interest (CoI) has been launched by The Pistoia Alliance, a global, non-profit alliance that promotes increased collaboration in life sciences R&D. Its goal is to calculate and compare the carbon footprints of...
Clinical Trials
GSKs Latecomer Jemperli Beats Keytruda In Lung Cancer Trial
The standard therapy for newly diagnosed metastatic non-small cell lung cancer is Keytruda by Merck. That is the standard that PD-1 latecomer GSK's Jemperli must meet, and the medication has succeeded in doing so.
In a phase 2 trial, individuals...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read